Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey

abur, ummet; ÖZATLI, Düzgün; TURGUT, Mehmet; Ogur, Gonul; Aymelek, Huri Sema; ALTUNDAĞ, ENGİN; AKAR, ÖMER SALİH

Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey

Ümmet ABUR, (Ondokuz Mayıs University Faculty of Medicine, Department of Medical Genetics, Samsun, Turkey)

Gönül OĞUR, (Ondokuz Mayıs University Faculty of Medicine, Department of Medical Genetics, Samsun, Turkey)

Ömer Salih AKAR, (Ondokuz Mayıs University Faculty of Medicine, Department of Medical Genetics, Samsun, Turkey)

Engin ALTUNDAĞ, (Ondokuz Mayıs University Faculty of Medicine, Department of Medical Genetics, Samsun, Turkey)

Huri Sema AYMELEK, (Ondokuz Mayıs University Faculty of Medicine, Department of Medical Genetics, Samsun, Turkey)

Düzgün ÖZATLI, (Ondokuz Mayıs University Faculty of Medicine, Department of Hematology, Samsun, Turkey)

Mehmet TURGUT (Ondokuz Mayıs University Faculty of Medicine, Department of Hematology, Samsun, Turkey)

Turkish Journal of Hematology

0 0

Yıl: 2018 Cilt: 35 Sayı: 1 Sayfa Aralığı: 61 - 65 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey

Öz:

Amaç: Bu çalışma, bir grup Türk kronik lenfositik lösemi (KLL) hastasında CLLU1 ekspresyonu ve floresan in situ hibridizasyon (FISH) analizinin prognostik etkisini değerlendirmektedir. Gereç ve Yöntemler: Yüz elli altı KLL hastası FISH yöntemiyle analiz edildi. Bu 156 hastanın 47'sinde ek olarak CLLU1 ekspresyonu incelendi. Sonuçlar klinik parametrelerle ilişkilendirildi. Bulgular: FISH aberasyonu, hastaların %62'sinde bulundu. Aberasyonların dağılımı del13q14 (%67), trizomi 12 (%27), del11q22 (%19), del17p (%8) ve 14q32'nin yeniden düzenlenmesi (%20) olarak bulundu. En yüksek mortalite, en kısa sağkalım süresi ve en fazla ilaç kullanımı del11q22 ve del17p grubunda idi. Homozigot 13q14 delesyonu, 14q32 yeniden düzenlenmesi ve yüksek CLLU1 ekspresyonu olan hastalar kısa sağkalıma sahipti. Sonuç: Sitogenetik/FISH analizi, KLL'nin prognostik değerlendirmesinde ve yeni genetik moleküler belirteçlerin belirlenmesinde halen etkili yöntemlerdir. del11q22, del17p, 14q32 yeniden düzenlenmesi ve homozigot del13q14'ün kötü prognostik etkisi gözden kaçırılmamalıdır. CLLU1'in KLL'de prognostik yeri tartışmalıdır. Çalışmamızda orta-kötü prognostik bir kriter olarak belirmesine rağmen, KLL'de rutin genetik testler arasına girebilmesi için daha fazla veri gereklidir.

Anahtar Kelime:

Konular: Hematoloji

Kronik Lenfositik Lösemi Hastalarının Prognozunda Floresan İn Situ Hibridizasyon Aberasyonları ve CLLU1 Ekspresyonunun Etkisi: Türkiye’den 156 Hastanın Sunumu

Öz:

Amaç: Bu çalışma, bir grup Türk kronik lenfositik lösemi (KLL) hastasında CLLU1 ekspresyonu ve floresan in situ hibridizasyon (FISH) analizinin prognostik etkisini değerlendirmektedir. Gereç ve Yöntemler: Yüz elli altı KLL hastası FISH yöntemiyle analiz edildi. Bu 156 hastanın 47’sinde ek olarak CLLU1 ekspresyonu incelendi. Sonuçlar klinik parametrelerle ilişkilendirildi. Bulgular: FISH aberasyonu, hastaların %62’sinde bulundu. Aberasyonların dağılımı del13q14 (%67), trizomi 12 (%27), del11q22 (%19), del17p (%8) ve 14q32’nin yeniden düzenlenmesi (%20) olarak bulundu. En yüksek mortalite, en kısa sağkalım süresi ve en fazla ilaç kullanımı del11q22 ve del17p grubunda idi. Homozigot 13q14 delesyonu, 14q32 yeniden düzenlenmesi ve yüksek CLLU1 ekspresyonu olan hastalar kısa sağkalıma sahipti. Sonuç: Sitogenetik/FISH analizi, KLL’nin prognostik değerlendirmesinde ve yeni genetik moleküler belirteçlerin belirlenmesinde halen etkili yöntemlerdir. del11q22, del17p, 14q32 yeniden düzenlenmesi ve homozigot del13q14’ün kötü prognostik etkisi gözden kaçırılmamalıdır. CLLU1’in KLL’de prognostik yeri tartışmalıdır. Çalışmamızda orta-kötü prognostik bir kriter olarak belirmesine rağmen, KLL’de rutin genetik testler arasına girebilmesi için daha fazla veri gereklidir.

Anahtar Kelime:

Konular: Hematoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Gentile M, Mauro FR, Guarini A, Foà R. New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. Curr Opin Oncol 2005;17:597-604.
2. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2004;163-183.
3. Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006;108:3152-3160.
4. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004;103:1202-1210.
5. Lai YY, Huang XJ. Cytogenetic characteristics of B cell chronic lymphocytic leukemia in 275 Chinese patients by fluorescence in situ hybridization: a multicenter study. Chin Med J (Engl) 2011;124:2417-2422.
6. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
7. Puiggros A, Blanco G, Espinet B. Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. Biomed Res Int 2014;2014:435983.
8. Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014:123:3247-3254.
9. Buhl AM, James DF, Neuberg D, Jain S, Rassenti LZ, Kipps TJ. Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. Eur J Haematol 2011;86:405-411.
10. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. Comparison of chromosome banding analysis, interphase and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002;16:53-59.
11. Josefsson P, Geisler CH, Leffers H, Petersen JH, Andersen MK, Jurlander J, Buhl AM. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 2007;109:4973-4979.
12. Ripollés L, Ortega M, Ortuño F, González A, Losada J, Ojanguren J, Soler JA, Bergua J, Coll MD, Caballín MR. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006;171:57-64.
13. Pittman S, Catovsky D. Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia. Br J Haematol 1984;58:649-660.
14. Cavazzini F, Hernandez JA, Gozzetti A, Russo Rossi A, De Angeli C, Tiseo R, Bardi A, Tammiso E, Crupi R, Lenoci MP, Forconi F, Lauria F, Marasca R, Maffei R, Torelli G, Gonzalez M, Martin-Jimenez P, Maria Hernandez J, Rigolin GM, Cuneo A. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. Br J Haematol 2008;142:529-537.
15. Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D, Kröber A, Kienle D, Lichter P, Döhner H. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007;92:1242-1245.
16. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006;24:4634-4641.
17. Puiggros A, Delgado J, Rodriguez-Vicente A, Collado R, Aventín A, Luño E, Grau J, Hernandez JÁ, Marugán I, Ardanaz M, González T, Valiente A, Osma M, Calasanz MJ, Sanzo C, Carrió A, Ortega M, Santacruz R, Abrisqueta P, Abella E, Bosch F, Carbonell F, Solé F, Hernández JM, Espinet B; Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC). Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. Br J Haematol 2013;163:47-54.
18. Buhl AM, Jurlander J, Geisler CH, Pedersen LB, Andersen MK, Josefsson P, Petersen JH, Leffers H. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Haematol 2006;76:455-464.
19. Gonzalez D, Else M, Wren D, Usai M, Buhl AM, Parker A, Oscier D, Morgan G, Catovsky D. CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes. Haematologica 2013;98:274-278.
20. Chen L, Li J, Zheng W, Zhang Y, Wu Y, Li L, Qian S, Xu W. The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma 2007;48:1785-1792.
21. Buhl AM, Jurlander J, Jørgensen FS, Ottesen AM, Cowland JB, Gjerdrum LM, Hansen BV, Leffers H. Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia. Blood 2006;107:2904-2911.

APA	abur u, Ogur G, AKAR Ö, ALTUNDAĞ E, Aymelek H, ÖZATLI D, TURGUT M (2018). Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. , 61 - 65.
Chicago	abur ummet,Ogur Gonul,AKAR ÖMER SALİH,ALTUNDAĞ ENGİN,Aymelek Huri Sema,ÖZATLI Düzgün,TURGUT Mehmet Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. (2018): 61 - 65.
MLA	abur ummet,Ogur Gonul,AKAR ÖMER SALİH,ALTUNDAĞ ENGİN,Aymelek Huri Sema,ÖZATLI Düzgün,TURGUT Mehmet Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. , 2018, ss.61 - 65.
AMA	abur u,Ogur G,AKAR Ö,ALTUNDAĞ E,Aymelek H,ÖZATLI D,TURGUT M Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. . 2018; 61 - 65.
Vancouver	abur u,Ogur G,AKAR Ö,ALTUNDAĞ E,Aymelek H,ÖZATLI D,TURGUT M Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. . 2018; 61 - 65.
IEEE	abur u,Ogur G,AKAR Ö,ALTUNDAĞ E,Aymelek H,ÖZATLI D,TURGUT M "Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey." , ss.61 - 65, 2018.
ISNAD	abur, ummet vd. "Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey". (2018), 61-65.

APA	abur u, Ogur G, AKAR Ö, ALTUNDAĞ E, Aymelek H, ÖZATLI D, TURGUT M (2018). Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. Turkish Journal of Hematology, 35(1), 61 - 65.
Chicago	abur ummet,Ogur Gonul,AKAR ÖMER SALİH,ALTUNDAĞ ENGİN,Aymelek Huri Sema,ÖZATLI Düzgün,TURGUT Mehmet Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. Turkish Journal of Hematology 35, no.1 (2018): 61 - 65.
MLA	abur ummet,Ogur Gonul,AKAR ÖMER SALİH,ALTUNDAĞ ENGİN,Aymelek Huri Sema,ÖZATLI Düzgün,TURGUT Mehmet Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. Turkish Journal of Hematology, vol.35, no.1, 2018, ss.61 - 65.
AMA	abur u,Ogur G,AKAR Ö,ALTUNDAĞ E,Aymelek H,ÖZATLI D,TURGUT M Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. Turkish Journal of Hematology. 2018; 35(1): 61 - 65.
Vancouver	abur u,Ogur G,AKAR Ö,ALTUNDAĞ E,Aymelek H,ÖZATLI D,TURGUT M Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. Turkish Journal of Hematology. 2018; 35(1): 61 - 65.
IEEE	abur u,Ogur G,AKAR Ö,ALTUNDAĞ E,Aymelek H,ÖZATLI D,TURGUT M "Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey." Turkish Journal of Hematology, 35, ss.61 - 65, 2018.
ISNAD	abur, ummet vd. "Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey". Turkish Journal of Hematology 35/1 (2018), 61-65.